ProMIS Neurosciences

ProMIS Neurosciences stock rose 16.1% in premarket trading after the presentation of six‑month, blinded interim results from the phase‑1b PRECISE‑AD study of PMN310. Among 136 patients there were no ARIA‑E cases; the overall incidence of ARIA was 4.4% and was limited to mild, asymptomatic microbleeds. There were no treatment‑related serious adverse events or study‑related discontinuations. The data are viewed as strong evidence of safety, particularly in APOE4 carriers, and were accompanied by new analyst coverage (Chardan: buy, price target $20.00), which drove the share price from $11.72 to $13.61. » Plus sur de.investing.com

ProMIS Neurosciences is hosting a webinar to discuss the blinded six-month interim results of the PRECISE-AD Phase 1b study for PMN310. Discussions will focus on aggregated safety data and trends in selected biomarkers from patients with early-stage Alzheimer’s. PMN310 is a humanized monoclonal IgG1 antibody that targets toxic amyloid‑beta oligomers without binding to plaques or vascular deposits, potentially reducing the risk of amyloid-related imaging abnormalities. The randomized, double-blind study of 144 participants across three dose cohorts is fully recruited; PMN310 received FDA Fast-Track designation in July 2025. » Plus sur de.investing.com

ProMIS Neurosciences has entered into a securities purchase agreement for a PIPE financing of up to $175 million, led by Janus Henderson and the Ally Bridge Group, with participation from new and existing investors as well as management and the board. Approximately $75 million is expected initially, with an additional $100 million if warrants are exercised; common shares, warrants and pre-funded warrants will be sold. The proceeds are intended to finance the phase 1b Alzheimer’s study and development of a subcutaneous formulation of PMN310; ProMIS is targeting blinded top-line data in mid‑2026 and 12‑month data by the end of 2026. The transaction is expected to close on February 3, 2026, subject to customary conditions. » Plus sur de.investing.com